Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT07432087 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

246

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Camrelizumab and Cetuximab
DRUG: Camrelizumab and Chemotherapy

Sponsor

Yue He, MD